H Lundbeck AS - Financial and Strategic Analysis ReviewSummaryH. Lundbeck A/S (Lundbeck) is a pharmaceutical company focused principally on the treatment of diseases of the central nervous system (CNS). The company is having major operations in the U.S. and Europe. In the CNS segment Lundbeck is developing drugs in five key areas namely; schizophrenia, Alzheimer's disease, depression, Parkinson's disease, and anxiety. The company's product portfolio includes Cipralex/Lexapro, Ebixa and Azilect. Cipralex or Lexapro (escitalopram) is helpful in the treatment of depression and anxiety. Ebixa (memantine) is used to cure Alzheimer's disease. Azilect (rasagiline) is prescribed against Parkinson's disease.Global Markets Direct, the leading business information provider, presents an in-depth business, strategic and financial analysis of H Lundbeck AS. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis and Global Markets Direct's views on the company.Scope-The company's strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational factors are considered. -The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are highlighted. -The report contains critical company information ' business structure and operations, the company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.-It provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters.-Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.Reasons to buy-A quick 'one-stop-shop' to understand the company. -Enhance business/sales activities by understanding customers' businesses better.-Get detailed information and financial & strategic analysis on companies operating in your industry.-Identify prospective partners and suppliers ' with key data on their businesses and locations.-Capitalize on competitors' weaknesses and target the market opportunities available to them.-Compare your company's financial trends with those of your peers / competitors.-Scout for potential acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
H Lundbeck AS - Financial and Strategic Analysis Review
Published on April 2009
Report Summary
H Lundbeck AS - Financial and Strategic Analysis Review
Summary
H. Lundbeck A/S (Lundbeck) is a pharmaceutical company focused principally on the treatment of diseases of the central nervous
system (CNS). The company is having major operations in the U.S. and Europe. In the CNS segment Lundbeck is developing drugs
in five key areas namely; schizophrenia, Alzheimer's disease, depression, Parkinson's disease, and anxiety. The company's product
portfolio includes Cipralex/Lexapro, Ebixa and Azilect. Cipralex or Lexapro (escitalopram) is helpful in the treatment of depression and
anxiety. Ebixa (memantine) is used to cure Alzheimer's disease. Azilect (rasagiline) is prescribed against Parkinson's disease.
Global Markets Direct, the leading business information provider, presents an in-depth business, strategic and financial analysis of H
Lundbeck AS. The report provides a comprehensive insight into the company, including business structure and operations, executive
biographies and key competitors. The hallmark of the report is the detailed strategic analysis and Global Markets Direct's views on the
company.
Scope
-The company's strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational
factors are considered.
-The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are
highlighted.
-The report contains critical company information ' business structure and operations, the company history, major products and
services, key competitors, key employees and executive biographies, different locations and important subsidiaries.
-It provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters.
-Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Reasons to buy
-A quick 'one-stop-shop' to understand the company.
-Enhance business/sales activities by understanding customers' businesses better.
-Get detailed information and financial & strategic analysis on companies operating in your industry.
-Identify prospective partners and suppliers ' with key data on their businesses and locations.
-Capitalize on competitors' weaknesses and target the market opportunities available to them.
-Compare your company's financial trends with those of your peers / competitors.
-Scout for potential acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Table of Content
H Lundbeck AS - Financial and Strategic Analysis Review Page 1/5

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Table Of Contents
Key Information 1
Key Ratios 1
Share Data 1
Performance Chart 1
Table Of Contents 2
List of Tables 3
List of Figures 3
Key Facts 4
Company Overview 4
Major Products and Services 5
Overview 5
History 6
SWOT Analysis Overview 8
Overview 8
H Lundbeck A/S - Strengths 8
Increasing Revenues of Cipralex and Lexapro 8
Market Presence 8
Diversified Geographies 8
H Lundbeck A/S - Weaknesses 8
Limited Scope of Diversification in the Biologics Sector 8
Discontinuation of gaboxadol 8
H Lundbeck A/S - Opportunities 8
In-licensing 8
Strategic Alliance with Takeda 8
Pharmaceutical Market in Japan 9
Changing Demographics 9
Rising Healthcare Expenditure in the US 9
H Lundbeck A/S - Threats 9
Increased Pricing Control 9
Competition 9
Tightening of the FDA's Regulatory Oversight 9
Industry Consolidation 10
Key Competitors 11
Key Employees 11
Key Employee Biographies 12
Company Statement 13
Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Financial Ratios 16
Capital Market Ratios 16
Annual Ratios 16
Interim Ratios 17
Ratio Charts 18
Appendix 19
Methodology 19
Ratio Definitions 19
About Global Markets Direct 22
Contact Us 22
H Lundbeck AS - Financial and Strategic Analysis Review Page 2/5

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Disclaimer 22
List of Tables
H Lundbeck A/S, Key Facts 1
H Lundbeck A/S, Key Ratios 1
H Lundbeck A/S, Share Data 1
H Lundbeck A/S, Key Facts 4
Major Products and Services 5
H Lundbeck A/S, History 6
H Lundbeck A/S, Key Employees 11
H Lundbeck A/S, Key Employee Biographies 12
H Lundbeck A/S, Other Locations 14
H Lundbeck A/S, Subsidiaries 15
H Lundbeck A/S, Ratios based on current share price 16
H Lundbeck A/S, Annual Ratios 16
H Lundbeck A/S, Interim Ratios 17
Currency Codes 19
Capital Market Ratios 19
Equity Ratios 19
Profitability Ratios 20
Cost Ratios 20
Liquidity Ratios 20
Leverage Ratios 21
Efficiency Ratios 21
List of Figures
H Lundbeck A/S, Performance Chart (2004 - 2008) 1
H Lundbeck A/S, Ratio Charts 18
H Lundbeck AS - Financial and Strategic Analysis Review Page 3/5

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
H Lundbeck AS - Financial and Strategic Analysis Review
Product Formats
Please select the product formats and the quantity you require.
Digital Copy--USD 125.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
H Lundbeck AS - Financial and Strategic Analysis Review Page 4/5

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
H Lundbeck AS - Financial and Strategic Analysis Review Page 5/5